About Paratek Pharma
Paratek Pharma is a company based in Boston (United States) founded in 1996 was acquired by Gurnet Point Capital in June 2023. Paratek Pharma has raised $96.48 million across 11 funding rounds from investors including Hercules Capital, HHS and Abingworth. The company has 205 employees as of December 31, 2021. Paratek Pharma has completed 2 acquisitions, including OptiNose and Transcept Pharmaceuticals. Paratek Pharma offers products and services including NUZYRA. Paratek Pharma operates in a competitive market with competitors including Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
- Headquarter Boston, United States
- Employees 205 as on 31 Dec, 2021
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Paratek Pharmaceuticals, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$96.48 M (USD)
in 11 rounds
-
Latest Funding Round
Not available
-
Investors
Hercules Capital
& 18 more
-
Employee Count
205
as on Dec 31, 2021
-
Investments & Acquisitions
OptiNose
& 1 more
-
Acquired by
Gurnet Point Capital
(Jun 06, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Paratek Pharma
Paratek Pharma offers a comprehensive portfolio of products and services, including NUZYRA.
FDA-approved tetracycline-class drug for treating bacterial infections.
People of Paratek Pharma
Unlock access to complete
Unlock access to complete
Sales and Marketing
63 people
Leadership Team
32 people
Software Development Team
32 people
Finance and Accounting
7 people
Product Management Team
5 people
Human Resources and Administration
4 people
Legal and Compliance
4 people
Key Team
3 people
Unlock access to complete
Funding Insights of Paratek Pharma
Paratek Pharma has successfully raised a total of $96.48M across 11 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Paratek Pharma
Paratek Pharma has secured backing from 19 investors, including institutional and venture fund investors. Prominent investors backing the company include Hercules Capital, HHS and Abingworth.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early stage venture capital firm investing in US
|
Locked | Locked | Locked | |
|
PE firm investing in the US
|
Locked | Locked | Locked | |
|
Life sciences focused VC firm funding companies in the US and Europe
|
Locked | Locked | Locked |
Investor details for Paratek Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Paratek Pharma
Paratek Pharma has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include OptiNose and Transcept Pharmaceuticals.
Investment portfolio details for Paratek Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of smart devices for nasal drug delivery
|
Locked | Locked | 2000 | Locked | |
|
Biopharmaceutical company with focus on drugs that target infectious disease, neuromuscular disease, and other difficult to treat conditions
|
Locked | Locked | 1996 | Locked |
Complete acquisition details for Paratek Pharma
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Paratek Pharma
Detailed financials for Paratek Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Paratek Pharma Comparisons
Peer comparison for Paratek Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Paratek Pharma
Paratek Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| Locked | Locked | Locked |
Pleuromutilin antibiotics are developed for MDR infections.
|
|
| Locked | Locked | Locked |
Developer of bacterial ribosome-targeting drugs for MDR infections
|
|
| Locked | Locked | Locked |
Developer of antibiotics for MDR infections
|
|
| Locked | Locked | Locked |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
Detailed competitors of Paratek Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Paratek Pharma
Complete news archive for Paratek Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Paratek Pharma
Paratek Pharma was founded in 1996 and raised its 1st funding round 6 years after it was founded.
Paratek Pharma is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Michael Bigham is the current CEO of Paratek Pharma.
Paratek Pharma is a funded company, having raised a total of $96.48M across 11 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Paratek Pharma is 205.
Paratek Pharma was founded in 1996 and is based in Boston, United States. Focus is placed on developing therapeutics to address antimicrobial resistant infections within the pharmaceutical sector. The lead product, NUZYRA (omadacycline), serves as an oral and intravenous antibiotic for treating community-acquired bacterial pneumonia and acute bacterial skin infections in adults. Seysara is also offered for managing inflammatory lesions in moderate to severe acne vulgaris.
Paratek Pharma's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
Paratek Pharma offers NUZYRA.
Paratek Pharma has made 2 acquisitions, including OptiNose, and Transcept Pharmaceuticals.
Paratek Pharma has 19 investors. Key investors include Hercules Capital, HHS, Abingworth, HBM Healthcare Investments, and Lombard Odier.